The last of our three cases reviewing management issues in elderly and frail patients with lung cancer, as covered in a recent webinar discussion I had with experts Paul J. Hesketh from Lahey Clinic and Karen Kelly from Kansas University Medical Center, focuses on treatment of advanced/metastatic NSCLC. Drs. Hesketh and Kelly are two of the world experts in this field that so desperately needs more research and careful thought, given that the median age of patients newly diagnosed with lung cancer in the US is now just over 70, and about a third of patients are frail, but our studies primarily or exclusively include younger, healthy patients. In fact, the figures include the reference of a review article that Dr. Hesketh is just publishing now in the Journal of Thoracic Oncology on treating patients 80 and older with lung cancer (it appears online but hasn't appeared in the actual printed journal yet).

Here is the audio and video versions of the podcast, along with the figures and transcript.

adv-nsclc-in-frail-and-elderly-patients-hesketh-and-kelly-audio-podcast

adv-nsclc-in-frail-and-elderly-patients-hesketh-and-kelly-transcript

adv-nsclc-in-frail-and-elderly-patients-hesketh-and-kelly-figs

As always, we welcome your thoughts and comments.

This program was made possible by an educational grant from OSI Pharmaceuticals, who had no input in its content. We thank them for their support.